Samil Pharmaceutical signs co-sales agreement of ‘Lastacaft Soln’ with Allergan
Samil Pharmaceutical(CEO Seung-Beom Huh) announced on 14 Mary that the company signed a distribution and co-sales agreement of Lastacaft Ophthalmic Solution 0.25% 5mL(alcaftadine), an allergic conjunctivitis therapy, with Allergan Korea(CEO Eun-Young Kim).
Thus, Samil Pharmaceutical has taken ov...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.